Epilepsy Research
Volume 31, Issue 2 , Pages 91-99 , July 1998

Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy

  • Barry E. Gidal

      Affiliations

    • School of Pharmacy, University of Wisconsin, 425 N. Charter Street, Madison, WI 53706, USA
    • Department of Neurology, University of Wisconsin, 425 N. Charter Street, Madison, WI 53706, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 608 2623280; fax: +1 608 2655421; e-mail: beg@pharmacy.wisc.edu
    • ,
  • John DeCerce

      Affiliations

    • University of Miami, International Center for Epilepsy, Miami, FL, USA
    • ,
  • Howard N. Bockbrader

      Affiliations

    • Warner-Lambert Co., Parke-Davis Pharmaceutical Research Division, Ann Arbor, MI, USA
    • ,
  • Jose Gonzalez

      Affiliations

    • University of Miami, International Center for Epilepsy, Miami, FL, USA
    • ,
  • Sarah Kruger

      Affiliations

    • Department of Neurology, University of Wisconsin, 425 N. Charter Street, Madison, WI 53706, USA
    • ,
  • Michael E. Pitterle

      Affiliations

    • School of Pharmacy, University of Wisconsin, 425 N. Charter Street, Madison, WI 53706, USA
    • ,
  • Paul Rutecki

      Affiliations

    • Department of Neurology, University of Wisconsin, 425 N. Charter Street, Madison, WI 53706, USA
    • ,
  • R.Eugene Ramsay

      Affiliations

    • University of Miami, International Center for Epilepsy, Miami, FL, USA

Received 2 December 1997 ,Revised 10 March 1998 ,Accepted 11 March 1998.

References 

  1. Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs Today. 1995;31:613–619
  2. Bockbrader HN, Breslin EM, Underwood BA, Posvar EL, Sedman AJ. Multiple-dose, dose-proportionality study of Neurontin (gabapentin) in health volunteers. Epilepsia. 1996;37(5):159
  3. Cramer JA, Mattson RH, Prevey ML, et al.  How often is medication taken as prescribed? A novel assessment technique. J. Am. Med. Assoc. 1989;261:3273–3277
  4. Gilbaldi, M., Perrier, D. (Eds.), 1975. Pharmacokinetics, vol. 1. Marcel Decker, New York.
  5. Heinzel, G., Woloszczak, R., Thomann, P., 1993. Topfit version 2.0: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Fischer, Stuttgart.
  6. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. 1996;60:601–607
  7. Lensmeyer G, Kempf T, Gidal B, Weibe D. Optimized method for determination of gabapentin in serum by HPL. Ther. Drug Monit. 1995;17:251–258
  8. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44:S17–S22
  9. Stevenson CM, Radulovic LL, Bockbrader HN, Fleisher D. Contrasting nutrient effects on the plasma levels of an amino acid like antiepileptic agent from the jejunal administration in dogs. J. Pharm. Sci. 1997;86:953–957
  10. Stevenson CM, Kim J, Fleisher D. Colonic absorption of antiepileptic agents. Epilepsia. 1997;38:63–67
  11. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res. 1993;10:276–282
  12. Vollmer KO, Anhut H, Thomann P, Wagner F, Jaehnchen D. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. Adv. Epileptol. 1989;17:209–211

PII: S0920-1211(98)00020-5

Epilepsy Research
Volume 31, Issue 2 , Pages 91-99 , July 1998

Article Tools

* Image Usage & Resolution